Why did Austal’s (ASX:ASB) stock surge on the day it announced a loss from its US division? It followed the Aussie shipbuilder trading and market update. Firstly Austal’s US division took a $175 million hit after the Department of War failed to grant relief on some legacy Navy contracts. That flipped a projected $110 million profit into a $113 million loss.

In the same announcement, Austal also revealed that South Korean defence giant Hanwha has offered up to US$1.2 billion for its American shipyards, the same shipyards that just lost $175 million. The market had been valuing that division at close to nothing, but to Hanwha it`s worth more than a billion dollars.

#finktok #defence #investing #money #stocks

DroneShield (ASX:DRO) launches RfRecon, a portable radio frequency (RF) intelligence system designed to help defence, government and security operators detect, identify and locate activity across the electromagnetic spectrum.

📡 Next-generation capability: RfRecon combines ultra-wideband spectrum awareness, precision direction finding and DroneShield’s RfAI-3 intelligence architecture in a single portable system, allowing operators to assess RF activity and gain greater operational context.
🛡️ Flexible deployment: The system is designed for dismounted, vehicle-mounted, rapid-deployment and fixed-site operations, with integration capabilities across existing defence and security ecosystems including Android Tactical Assault Kit (ATAK) and third-party command-and-control platforms.
🌍 Market rollout: DroneShield has begun engagement with qualified defence, government and security customers globally. Subject to procurement timelines, the company expects potential orders and revenue contribution to commence in the second half of 2026, although no sales value has yet been quantified.

“The teams that gain the greatest advantage will be those that can rapidly understand what they are seeing and confidently act on it. RfRecon reflects that shift by bringing RF intelligence directly to the tactical edge.” – Angus Bean, DroneShield CEO and Managing Director

Why is the Pentagon backing a mine in central New South Wales? Because of a metal you`ve probably never heard of, scandium. Scandium is to make lightweight alloys for aircraft, advanced semiconductors and fuel cells powering AI data centres.

China dominates global supply and America hasn`t mined it domestically in decades, so the US Department of War has conditionally committed up to US$400 million towards Sunrise Energy Metals’ (ASX:SRL) deposit.

Countries have always competed for oil and now they`re competing for ingredients too. That`s great news for companies like Sunrise, its share price has surged more than 130% this year alone.

#mining #US #stocks #wallstreet #defence

Tennant Minerals (ASX:TMS) is preparing for the next phase of work at its Bluebird high-grade copper-gold-bismuth discovery, following confirmation that mineralisation extends beyond the current open-pit Mineral Resource in the Northern Territory. With $2.8 million raised, the company is now advancing step-out drilling, geological modelling and metallurgical studies aimed at defining the broader opportunity and progressing development pathways. Tennant Minerals General Manager Chris Ramsay joins The Stock Network’s Lel Smits to discuss what comes next for Bluebird and how the latest work is moving the project towards development.

🪓 From discovery to defining the system
⚒️ Testing the bigger Bluebird opportunity
🚀 Building towards development

Vection Technologies (ASX:VR1) has received $1.2 million in non-repayable, non-dilutive government funding across four R&D programs spanning artificial intelligence, extended reality and digital health.

💰 Government funding: The $1.2 million in cash will support Vection Technologies’ existing product roadmap, expand collaboration opportunities and strengthen working capital without dilution to shareholders.
🩺 Digital health development: The AI-powered Digital Health Rehabilitation (OMNIREHAB) program is developing an AI-powered remote rehabilitation platform combining motion capture and Extended Reality (XR) for home-based cognitive and physical rehabilitation.
🤖 Broader technology pipeline: The funding also supports projects focused on inclusive AI and sign-language translation, cultural and museum AI, and immersive heritage visualisation, with research partners including University College London (UCL), the National Research Council of Italy (CNR) and several Italian universities.

"The technologies and capabilities we are developing will be integrated into Algho AI and IntegratedXR, while other activities will generate standalone intellectual property." – Gianmarco Biagi, Vection Technologies Managing Director and Executive Chairman

Austco Healthcare (ASX:AHC) strengthens its direct presence in the Australian healthcare market, agreeing to acquire long-standing South Australian reseller Medical Communications Systems (MCS) for approximately $2.88 million.

🏥 Strategic acquisition: Austco will acquire 100% of MCS, bringing its South Australian nurse call reseller in-house and strengthening direct customer relationships and service delivery in the state.
💰 Earnings accretive: The transaction comprises approximately $2.24 million in upfront cash and an estimated $0.64 million performance-based earnout. On a full-year basis, MCS is expected to contribute approximately $1.88 million of incremental revenue and $0.82 million of EBITDA.
📈 Proven M&A strategy: The acquisition follows Austco’s previous reseller acquisitions of Teknocorp, Amentco and G&S Technologies. MCS has been an Austco-certified reseller since 2011, with its 12 staff expected to remain with the business.

“This acquisition follows the same disciplined model as our last three acquisitions: strengthening our direct sales capability, deepening our customer relationships and retaining experienced local people.” – Clayton Astles, Austco Healthcare CEO

Braveheart Bio (NASDAQ: BRVE) just raised $440 million to list on the Nasdaq. It was founded two years ago, and its primary drug treats a heart condition where the muscle thickens and struggles to pump.

Braveheart didn`t invent the drug, they licensed it from a pharmaceutical company in China, every clinical trial so far was designed and run entirely by that Chinese company. Braveheart wasn`t involved and doesn`t manufacture the drug. What Braveheart bought was the exclusive right to seek FDA approval and sell the drug everywhere, except Greater China.

There have been more than one hundred similar licensing deals since the start of last year. Increasingly, cutting-edge medicines are invented in China and sold to you by American biotechs.

#biotech #stocks #nasdaq #IPO #fintok

Patrys (ASX:PAB) is advancing its lead drug candidate, RLS-2202, towards its first clinical trial in humans. During the June quarter, Patrys appointed a specialist clinical trial site and contract research organisation, progressed its trial protocol and submitted its ethics application. The company is now targeting first participant dosing in Q3 2026, subject to the required approvals. Patrys CEO Dr Samantha South joins The Stock Network`s Lel Smits to discuss RLS-2202, the company`s path into the clinic and what investors can expect next.

⚕️ Getting RLS-2202 into the clinic
🔬 What RLS-2202 could do
🚀 What`s next for Patrys